2026-10-11T17:57:58Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34041053 2026-10-01T07:23:02Z category_37339 category_37351 category_37357 category_37363 category_37366 portal_1012 item_type_6 month_year_10_2026

Supplementary Figure S1 from Tumor-Infiltrating Lymphocytes as a Predictor of Adjuvant Avelumab Efficacy in Patients with High-risk Triple-Negative Breast Cancer Maria Vittoria Dieci (15026025) Elisa Gasparini (17726790) Lorenzo Nicolé (25154735) Peter Schmid (17977711) Alberto Zambelli (16677474) Adolfo Favaretto (25154738) Federico Piacentini (15026040) Giulia Valeria Bianchi (25154741) Marta Mion (25154744) Antonella Ferro (25154747) Grazia Arpino (15030978) Alessandra Emiliani (25154750) Saverio Cinieri (24205938) Claudio Zamagni (20018437) Alessandra Gennari (16006047) Simon Spazzapan (25154753) Donata Sartori (25154756) Fable Zustovich (25154759) Stefano Tamberi (17647117) Lucia Del Mastro (15030993) Michelino de Laurentiis (25154762) Antonino Musolino (14956011) Katia Cagossi (21365614) Daniele Generali (15030987) Tommaso Giarratano (15038127) Filippo Giovanardi (25154765) Gian Luca De Salvo (15023229) Pierfranco Conte (15026049) Valentina Guarneri (16677480) Cancer Tumor Biology Cancer Detection and Diagnosis Immuno-oncology Clinical Research and Trials Biomarkers Prognostic biomarkers Breast Cancer Clinical Trial Results Phase III clinical trials Immunotherapy Checkpoint blockade Tumor Microenvironment Immune cells and the microenvironment <p>Prognostic role of BSL-TILs in Stratum A. Kaplan-Meier curves according to BSL-TILs>30% vs <30% for DFS (A), DDFS (B), OS (C). Univariate cox regression HR and 95%CI for BSL-TILs 5% increments are also reported for each survival outcome.</p> 2026-10-01T00:00:00Z Text Journal contribution 10.1158/1078-0432.34041053 https://figshare.com/articles/journal_contribution/Supplementary_Figure_S1_from_Tumor-Infiltrating_Lymphocytes_as_a_Predictor_of_Adjuvant_Avelumab_Efficacy_in_Patients_with_High-risk_Triple-Negative_Breast_Cancer/34041053 CC BY